Document Detail


Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome.
MedLine Citation:
PMID:  20156067     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Obese women with polycystic ovary syndrome (PCOS) manifest impaired insulin-stimulated release of a d-chiro-inositol-containing inositolphosphoglycan (DCI-IPG) insulin mediator during oral glucose tolerance testing (OGTT), which appears to be restored by the administration of metformin. This suggests that either obesity or PCOS is associated with a defect in the coupling of the stimulation of the insulin receptor by insulin to the release of the DCI-IPG mediator. The objective of this study was to compare the release of bioactive DCI-IPG between normal nonobese women and obese PCOS women during stimulation with two different concentrations of insulin when glucose levels are clamped.
METHODS: We performed a cross-sectional case-control study at the clinical research center of an academic medical center. A two-step euglycemic-hyperinsulinemic clamp was carried out in 8 nonobese normal and 8 obese PCOS women, during which DCI-IPG bioactivity was monitored.
RESULTS: At baseline, PCOS women were significantly more obese, hyperinsulinemic, and insulin resistant than the controls. During the clamp studies, DCI-IPG bioactivity increased significantly over the first 45 min of the low-insulin step of the clamp in normal nonobese women (P = 0.046) and then decreased to baseline levels; DCI-IPG increased again after initiation of the high-insulin step (P = 0.029). Despite higher insulin levels during the clamp in PCOS women, DCI-IPG bioactivity remained flat throughout both insulin steps and was thus significantly lower than in controls during the initial periods of both steps.
CONCLUSIONS: The coupling between insulin action and the release of the DCI-IPG mediator is selectively impaired in obese PCOS women, which may contribute to the insulin resistance in these women.
Authors:
Jean-Patrice Baillargeon; Maria J Iuorno; Teimuraz Apridonidze; John E Nestler
Related Documents :
18375437 - Metformin decreases the adipokine vaspin in overweight women with polycystic ovary synd...
10899497 - Prevalence of 21-hydroxylase-deficient nonclassic adrenal hyperplasia and insulin resis...
20540677 - The quantitative insulin sensitivity check index is not able to detect early metabolic ...
7723677 - Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome.
7999057 - Obese zucker (fa/fa) rats are resistant to insulin's inhibitory effect on hepatic apo b...
16594577 - Use of glargine and lente insulins in cats with diabetes mellitus.
Publication Detail:
Type:  Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Metabolic syndrome and related disorders     Volume:  8     ISSN:  1557-8518     ISO Abbreviation:  Metab Syndr Relat Disord     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-04-07     Completed Date:  2010-08-06     Revised Date:  2011-08-25    
Medline Journal Info:
Nlm Unique ID:  101150318     Medline TA:  Metab Syndr Relat Disord     Country:  United States    
Other Details:
Languages:  eng     Pagination:  127-36     Citation Subset:  IM    
Affiliation:
Department of Medicine, Division of Endocrinology, Université de Sherbrooke, Sherbrooke, Quebec, Canada. JP.Baillargeon@USherbrooke.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Case-Control Studies
Cross-Sectional Studies
Diazoxide / administration & dosage,  pharmacology
Female
Glucose Clamp Technique
Humans
Hypoglycemic Agents / administration & dosage,  pharmacology
Inositol / chemistry,  secretion*
Inositol Phosphates / chemistry,  metabolism,  secretion*
Insulin / administration & dosage,  blood,  metabolism*,  pharmacology
Obesity / blood,  complications,  metabolism*
Polycystic Ovary Syndrome / blood,  complications,  metabolism*
Polysaccharides / chemistry,  metabolism,  secretion*
Signal Transduction / drug effects
Young Adult
Grant Support
ID/Acronym/Agency:
K24HD40237/HD/NICHD NIH HHS; R01 HD035629-13/HD/NICHD NIH HHS; R01HD35629/HD/NICHD NIH HHS
Chemical
Reg. No./Substance:
0/Hypoglycemic Agents; 0/Inositol Phosphates; 0/Polysaccharides; 0/inositol phosphate glycan; 11061-68-0/Insulin; 364-98-7/Diazoxide; 6917-35-7/Inositol
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cutoffs of Abdominal Adipose Tissue Compartments as Measured by Magnetic Resonance Imaging for Detec...
Next Document:  Diagnostic Criteria for Metabolic Syndrome: Caucasians Versus African-Americans.